Rosiglitazone alleviates injury in rats with adenine‑induced chronic kidney disease

Huang,Ying; Lei,Yan; Zheng,Zhihua; Wang,Xiaohua; Hu,Mingliang; Liu,Rongjun; Yu,Xueqing

doi:10.3892/mmr.2013.1715

Rosiglitazone alleviates injury in rats with adenine‑induced chronic kidney disease

Authors:
- Ying Huang
- Yan Lei
- Zhihua Zheng
- Xiaohua Wang
- Mingliang Hu
- Rongjun Liu
- Xueqing Yu
View Affiliations

Affiliations: Department of Nephrology, The First Affiliated Hospital, Sun Yat‑Sen University, Key Laboratory of Nephrology, Ministry of Health, Guangzhou, Guangdong 510080, P.R. China
Published online on: October 8, 2013 https://doi.org/10.3892/mmr.2013.1715
Pages: 1831-1835

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rosiglitazone (ROG) has been shown to exert beneficial effects on glycemic control and renal protection. Circulatory fibroblast growth factor‑23 (FGF‑23) is a novel independent risk factor for chronic kidney disease (CKD) progression. The current study focused on how ROG impacts on injury of the kidney, and whether FGF‑23 is involved in the process. A total of 24 male Sprague Dawley rats, weighing 250‑280 g, were divided into four groups (n=6 per group): i) Normal; ii) ROG controls, treated with ROG (10 mg/kg/day); iii) CKD models, treated with adenine (200 mg/kg/day); and iv) ROG treatment, treated with ROG (10 mg/kg/day) and adenine (200 mg/kg/day). The rats were sacrificed after four weeks, and serum, urine and kidney tissues were collected. The data revealed that the serum levels of inorganic phosphate (Pi), intact parathyroid hormone (iPTH) and FGF‑23 were significantly higher in the CKD models compared with those in the normal group (P<0.01), while ROG significantly reduced the serum levels of Pi, iPTH and FGF‑23 (P<0.01). The ratio of protein/creatine (Cr) in the urine and the serum levels of Cr, blood urea nitrogen and uric acid were significantly increased in the CKD models compared with the normal group (P<0.01), however, ROG significantly reduced these parameters (P<0.05). Furthermore, ROG significantly alleviated the tubule interstitial damage index of the CKD models in comparison with that of the controls. These results indicated that ROG mitigates the lesions of chronic kidney disease induced by adenine, and that the system of Pi‑PTH‑FGF‑23 may contribute to this process. The possible mechanisms underlying this process require confirmation in future studies.

View Figures

View References

1	Bello AK, Hemmelgarn B, Lloyd A, James MT, Manns BJ, Klarenbach S, et al: Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin J Am Soc Nephrol. 6:1418–1426. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sarnak MJ and Astor BC: Implications of proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis. 18:258–266. 2011. View Article : Google Scholar : PubMed/NCBI
3	Faul C: Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens. 21:369–375. 2012. View Article : Google Scholar : PubMed/NCBI
4	Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, et al: Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone. 50:1266–1274. 2012. View Article : Google Scholar : PubMed/NCBI
5	Razzaque MS and Lanske B: The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol. 194:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
6	Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 113:561–568. 2004. View Article : Google Scholar : PubMed/NCBI
7	Seiler S, Heine GH and Fliser D: Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl. 76:S34–S42. 2009. View Article : Google Scholar : PubMed/NCBI
8	El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, et al: Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 75:1297–1307. 2009. View Article : Google Scholar : PubMed/NCBI
9	Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 359:584–592. 2008.PubMed/NCBI
10	Sharma SK, Zou H, Togtokh A, Ene-Iordache B, Carminati S, Remuzzi A, et al: Burden of CKD, proteinuria, and cardiovascular risk among Chinese, Mongolian, and Nepalese participants in the International Society of Nephrology screening programs. Am J Kidney Dis. 56:915–927. 2010. View Article : Google Scholar : PubMed/NCBI
11	Reel B, Guzeloglu M, Bagriyanik A, Atmaca S, Aykut K, Albayrak G and Hazan E: The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats. J Surg Res. 182:176–184. 2013.
12	Basturk T, Unsal A, Ulas T, Koc Y, Sakaci T, Ahbap E and Borlu F: Effects of rosiglitazone treatment on insulin resistance and TNF-alpha levels in patients with chronic kidney disease: a prospective study. Eur Rev Med Pharmacol Sci. 16:1519–1524. 2012.PubMed/NCBI
13	Setti G, Hayward A, Dessapt C, Barone F, Buckingham R, White K, et al: Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Am J Nephrol. 32:393–402. 2010.
14	Ren L, Liu N, Zhi H, Li Y, Li Y, Tang R, et al: Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Cardiovasc Diabetol. 10:102011. View Article : Google Scholar : PubMed/NCBI
15	Alessi A, França Neto OR, Prim C, Silva RF, Noronha Ld, Brofman PR, et al: Rosiglitazone and vascular injury in hypercholesterolemic rabbits: neointimal formation assessment. Arq Bras Cardiol. 95:283–288. 2010.PubMed/NCBI
16	Nakaya H: Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice. Nihon Rinsho. 68:229–234. 2010.(In Japanese).
17	Schiffrin EL: Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol. 288:H1037–H1043. 2005. View Article : Google Scholar : PubMed/NCBI
18	Hu W, Yu Q, Zhang J and Liu D: Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation. 35:1287–1293. 2012. View Article : Google Scholar : PubMed/NCBI
19	Bergwitz C and Jüppner H: Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 61:91–104. 2010. View Article : Google Scholar : PubMed/NCBI
20	Pontoriero G, Cozzolino M, Locatelli F and Brancaccio D: CKD patients: the dilemma of serum PTH levels. Nephron Clin Pract. 116:c263–c268. 2010. View Article : Google Scholar : PubMed/NCBI
21	Levin A, Djurdjev O, Beaulieu M and Er L: Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis. 52:661–671. 2008. View Article : Google Scholar : PubMed/NCBI
22	Kincaid-Smith P, Fairley KF, Farish S, Best JD and Proietto J: Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton). 13:58–62. 2008. View Article : Google Scholar : PubMed/NCBI
23	Betz B, Schneider R, Kress T, Schick MA, Wanner C and Sauvant C: Rosiglitazone affects nitric oxide synthases and improves renal outcome in a rat model of severe ischemia/reperfusion injury. PPAR Res. 2012:2193192012. View Article : Google Scholar : PubMed/NCBI